Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc.
Your view on TNDM
Overview
What the company does, where it operates, and who runs it.
About Tandem Diabetes Care, Inc.
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- John F. Sheridan
- Headquarters
- 11075 Roselle Street, San Diego, CA, US
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- John F. Sheridan
- Headquarters
- 11075 Roselle Street, San Diego, CA, US
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally.
The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software.
In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin.
It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Tandem Diabetes Care, Inc., and the rating behind it. TNDM last traded at $17.11; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Tandem Diabetes Care, Inc.. Starting points for Tandem Diabetes Care, Inc.: EPS -$0.93, beta 1.56 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Tandem Diabetes Care, Inc.. Tandem Diabetes Care, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Tandem Diabetes Care, Inc.. Trailing twelve-month EPS for Tandem Diabetes Care, Inc. stands at -$0.93. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Tandem Diabetes Care, Inc.. Tandem Diabetes Care, Inc. has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Tandem Diabetes Care, Inc. valued side by side against its closest peers. Tandem Diabetes Care, Inc. is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Tandem Diabetes Care, Inc., and how their positions are changing. At a $1.17B market value, institutional positions materially move Tandem Diabetes Care, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Tandem Diabetes Care, Inc. executives and directors. Shares of Tandem Diabetes Care, Inc. have traded between $9.98 and $38.28 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Tandem Diabetes Care, Inc.. Tandem Diabetes Care, Inc. is a $1.17B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Tandem Diabetes Care, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Tandem Diabetes Care, Inc.. Coverage tracks Tandem Diabetes Care, Inc. within Medical - Devices (Healthcare). Press releases and market coverage, newest first.